Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2010 1
2011 1
2012 4
2013 2
2014 2
2016 1
2017 1
2018 1
2019 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL. Lorusso D, et al. Among authors: samyshkin y. Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285. Cancers (Basel). 2022. PMID: 35267593 Free PMC article. Review.
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Nikolaou A, et al. Among authors: samyshkin y. Expert Rev Hematol. 2021 Dec;14(12):1137-1145. doi: 10.1080/17474086.2021.1970522. Epub 2021 Sep 20. Expert Rev Hematol. 2021. PMID: 34465265
High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project.
Bergemann R, Allsopp J, Jenner H, Daniels FA, Drage E, Samyshkin Y, Schmitt C, Wood S, Kiely DG, Lawrie A; SPHInX Project team. Bergemann R, et al. Among authors: samyshkin y. Pulm Circ. 2018 Oct-Dec;8(4):2045894018798613. doi: 10.1177/2045894018798613. Pulm Circ. 2018. PMID: 30187824 Free PMC article.
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3. Value Health. 2017. PMID: 28292484 Free article.
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2016 Sep-Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21. Value Health. 2016. PMID: 27712708 Free article.
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs AH, Lloyd A, Sullivan SD, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14. Value Health. 2014. PMID: 25128045 Free article.
20 results